Moreover, we did not find significant differences in plasma levels of EVs bearing FasL at baseline and post-treatment, but we did find correlations between FasL-expressing EVs and plasma levels of biomarkers for AIDS-NHL risk (sCD44, CXCL10, and TNF-α) at baseline, suggesting that they can mediate tumor immune responses and/or tumor immune escape. The gene discussed is CXCL10; the disease is non-Hodgkin lymphoma.